Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray

Hans Matter1, David W Will, Marc Nazaré

  • 1DI and A Chemistry, Aventis Pharma Deutschland GmbH, A Company of the Sanofi-Aventis Group, Building G 878, D-65926 Frankfurt am Main, Germany. hans.matter@aventis.com